Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 9/20 | 0.51 |
| ▸ | EDNRA | P25101 | 6/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795096 | 0.86 | EDNRB (0.62) | EDNRBEDNRACCR2KMT2AALDH1A1 | |
| SCHEMBL6313613 | 0.85 | EDNRB (0.49) | EDNRBEDNRAHTTPTPN1MAPT | |
| SCHEMBL6314849 | 0.84 | EDNRB (0.62) | EDNRBEDNRA | |
| SCHEMBL6319417 | 0.81 | EDNRB (0.50) | EDNRBEDNRAKMT2AATMKDM4E | |
| SCHEMBL6313623 | 0.80 | EDNRB (0.51) | EDNRBEDNRAKDM4EPLA2G1BPLA2G2A | |
| SCHEMBL6314856 | 0.79 | EDNRB (0.52) | EDNRBEDNRAKMT2AKDM4EPLA2G1B | |
| SCHEMBL6663213 | 0.78 | EDNRB (0.44) | EDNRBEDNRAHTTPLA2G1BPLA2G2A | |
| SCHEMBL6658446 | 0.77 | EDNRB (0.61) | EDNRBEDNRAMAPT | |
| SCHEMBL8553006 | 0.76 | EDNRB (0.62) | EDNRBEDNRAKDM4EPLA2G1BPLA2G2A | |
| SCHEMBL8551759 | 0.75 | EDNRB (0.62) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | claimed |
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014769-A1 | Use of endothelin receptor antogonists for the treatment of tumour diseases | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885HTT 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.